Sanyou Medical released its 2026 interim report. Operating revenue was 274 million yuan, up 9.7% year-on-year. Net profit attributable to the parent was 27.75 million yuan, down 24.2% year-on-year. Net profit attributable to the parent after deducting non-recurring items was 14.25 million yuan, down 45.2% year-on-year. Second-quarter operating revenue was 150 million yuan, up 12.8% year-on-year, and net profit attributable to the parent was 20.7 million yuan, down 13.0% year-on-year. The company said that after excluding share-based payment expenses, asset and credit impairment losses, and foreign exchange losses, net profit attributable to the parent achieved substantial growth. It also invested in Zhuiyuan Medical to strengthen its layout in the cell therapy field.
Shanghai Sanyou Medical Co LtdNet profit attributable to parent fell 24.2% year-on-year, despite revenue growth.
